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antiretroviral therapy
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N Kumarasamy, Praphan Phanuphak, Pierre deBeaudrap, Marco Vitoria, Meg Doherty, Wendy Stevens, George K Siberry
For more than two decades, CD4 cell count measurements have been central to understanding HIV disease 
progression, making important clinical decisions, and monitoring the response to antiretroviral therapy (ART). In 
well resourced settings, the monitoring of patients on ART has been supported by routine virological monitoring. 
Viral load monitoring was recommended by WHO in 2013 guidelines as the preferred way to monitor people on ART, 
and eﬀ orts are underway to scale up access in resource-limited settings. Recent studies suggest that in situations 
where viral load is available and patients are virologically suppressed, long-term CD4 monitoring adds little value and 
stopping CD4 monitoring will have major cost savings. CD4 cell counts will continue to play an important part in 
initial decisions around ART initiation and clinical management, particularly for patients presenting late to care, and 
for treatment monitoring where viral load monitoring is restricted. However, in settings where both CD4 cell counts 
and viral load testing are routinely available, countries should consider reducing the frequency of CD4 cell counts or 
not doing routine CD4 monitoring for patients who are stable on ART.
Introduction
For more than two decades CD4 cell count measurements 
have been central to understanding HIV disease 
progression and making important clinical management 
decisions. Measurements of CD4 cell count are an 
important predictor of disease progression1–5 and death6–8 
in people living with HIV and have been the main means 
to assess eligibility for initiation of antiretroviral therapy 
(ART), use of prophylaxis for opportunistic infections, 
and monitoring the response to treatment.8–10
In well resourced settings, monitoring of patients 
on ART has been supported by routine virological 
monitoring.11 Viral load (plasma HIV RNA) monitoring 
also predicts HIV-related mortality, accurately detects 
virological failure usually before immunological or 
clinical deterioration, and signals the need for more 
intensive adherence support and resistance 
genotyping.12,13 Recog nising these beneﬁ ts, WHO 
recommends measurement of HIV viral load as the 
preferred approach to treatment monitoring,14 and 
concerted eﬀ orts are supporting scale-up of viral load 
capability in resource-limited settings.15
As access to viral load becomes increasingly available, 
the role of CD4 monitoring in virologically suppressed 
patients is increasingly being questioned. Several studies 
have recently suggested that CD4 cell count monitoring 
has little added value in situations where viral load is 
available and patients are virologically suppressed.16–18
In September, 2013, WHO held an expert consultation 
on the future role of CD4 testing for ART monitoring. 
We summarise the evidence and experience shared and 
the conclusions reached at this consultation.
Current policies for ART monitoring
During the past decade, WHO guidelines for ART in 
countries with low and middle incomes have evolved 
towards recommending that countries phase in viral load 
for monitoring of treatment. The value of viral load was 
recognised by WHO guidelines in 2003, although access at 
the time was restricted by the complexity and cost of 
available assays.19 Since then, improvements in technology 
and access have led to increased use of viral load 
monitoring. WHO guidelines released in June, 2013, 
recommend that countries use HIV viral load as the 
preferred approach to ART monitoring.20,21
Guidelines for ART monitoring vary between 
countries. Several resource-limited settings, including 
Mozambique, Swaziland, and Zimbabwe rely on routine 
CD4 monitoring, with viral load used only in a targeted 
way to conﬁ rm virological failure in patients with 
immunological or clinical failure. Other countries, 
including Cameroon and Côte d’Ivoire, provide both 
CD4 cell counts and viral load measurement routinely, 
albeit with diﬀ erent frequencies. Malawi and South 
Africa rely on viral load for long-term monitoring. In 
South Africa, discontinuation of routine CD4 cell count 
is now recommended after 1 year for patients stable on 
ART, although CD4 cell counts are done when needed 
for decisions regarding the stopping of prophylaxis for 
some AIDS-associated opportunistic infections.22 
Monitoring strategies can also diﬀ er between public and 
private sectors: in India for example, targeted use of viral 
load is provided in the public sector, whereas routine 
viral load monitoring is oﬀ ered in the private sector. The 
frequency of CD4 cell counts and viral load tests for ART 
monitoring also varies substantially between countries 
(table).
Prospects to increase access to viral load 
monitoring
Although viral load measurement is recommended by 
WHO as the preferred approach to treatment monitoring 
and is included in guidelines of most countries with high 
HIV burden, access is restricted. Several middle-income 
countries—notably Botswana, Brazil, South Africa, and 
Thailand—were early adopters of HIV viral load 
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monitoring, integrating it into their ART scale-up plans 
from the outset. Viral load monitoring has been 
integrated into public health programmes more broadly 
since 2010, when WHO guidelines ﬁ rst recommended 
that countries should phase in viral load for routine 
treatment monitoring (ﬁ gure).23
One of the most important barriers to the scaling up 
of viral load testing remains cost: for low and middle 
income countries test costs vary from around US$10 to 
more than US$50. The African Society for Laboratory 
Medicine recommends several approaches to reduce 
the cost of viral load testing, including negotiating 
volume-based regional or country-wide pricing for test 
supplies, leasing equipment if possible, encouraging 
competition between suppliers, and leveraging existing 
laboratory capacity and systems established for early 
infant diagnosis of HIV to support the scale-up of viral 
load monitoring.15
A key consideration to increase resource availability 
for phasing in viral load testing is to decrease the 
overall cost of laboratory monitoring. Recent modelling 
studies from South Africa24 and the USA25 have 
suggested that reducing the frequency of CD4 cell 
count monitoring can substantially reduce the overall 
cost of ART monitoring and thereby avoid unnecessary 
use of resources. In resource-limited settings, these 
resources could be directed towards increasing access 
to viral load.
The anticipated arrival of point-of-care technologies in 
the near future is expected to overcome some of the 
technological limitations to improving access to viral 
load, particularly in remote rural areas. As of March, 2014, 
nine point-of-care technologies were in the pipeline with 
six anticipated to receive market authorisation by 2016.26 
Other approaches that have been taken to increase 
capacity and access include the use of dried blood spot 
sample collection and sample pooling.27,28
The future of CD4 cell count for treatment 
initiation
The WHO 2013 Consolidated ART guidelines recommend 
that ART be initiated for all patients with CD4 count 
500 cells per μL or less, and immediate initiation of ART 
regardless of CD4 count for children age up to 5 years, 
people with active tuberculosis or with hepatitis B 
co-infection and chronic liver disease, and HIV-infected 
people in serodiscordant partnerships; these guidelines 
further recommend that ART be immediately oﬀ ered to 
all HIV-infected pregnant and breastfeeding women.29
Most high-burden countries are in the process of 
adopting and adapting these WHO recommendations 
according to their epidemic setting and resource 
availability. As of June, 2013, 19 countries had allowed for 
immediate ART in HIV serodiscordant couples, ﬁ ve 
countries had adopted an ART initiation threshold of CD4 
count 500 cells per μL, and 12 countries had moved to 
immediate ART for all pregnant and breastfeeding 
women.30 A few countries already oﬀ er ART to all patients 
irrespective of CD4 cell count,31 or are considering to do so.
Thus, although there is a trend towards an increasing 
number of CD4-independent ART initiation scenarios, 
ART for all irrespective of CD4 cell count remains the 
exception rather than the rule, and for most countries 
CD4 measures will continue to play an important part to 
determine ART eligibility for some time to come.
CD4 cell count 
monitoring
Viral load monitoring Future perspective
India
Public sector 6 monthly Targeted Routine: annually
Private sector 3–6 monthly Routine: 6 months, then annually Routine
Mozambique 6 monthly Targeted Evolution towards routine 
viral load
Botswana 3 months, 6 months, 
then 6 monthly
Adults: 3 months, 6 months, then 
6 monthly; children: 3 monthly
Annual CD4
Cameroon Every 6 months Viral load should be tested at 
6 months, 12 months, then every 
2 years if viral load undetectable 
(ie, <5000 cell parts/mL)
CD4 tested every 6 months 
until 2 measures >350 cells.uL 
then stopped viral load tested 
at 6 months, 12 months, then 
annually
South Africa At 12 months, then 
stop
Routine: 6 months, 12 months, 
then annually
Routine
Brazil 4 monthly 4 monthly 6 monthly
Thailand 6 monthly Routine: 6 months, 12 months, 
then annually
Annual CD4 once virologically 
suppressed
Côte d’Ivoire 6 monthly Adults: annually; children: 
6 monthly
Routine
Malawi* None Routine: 6 months, then every 
2 years
Routine
DR Congo* 6 monthly Targeted Unclear
Guinea* 6 monthly Targeted Unclear
Kenya* 6 monthly Routine: annually Consideration to drop CD4 
monitoring in stable patients
Lesotho* 6 monthly Routine: annually Routine
Swaziland* 6 monthly Targeted; routine: annually Consideration to drop CD4 
monitoring in stable patients
Zimbabwe* 6 monthly Targeted Evolution towards routine 
viral load
Myanmar* 6 monthly Targeted Routine
Ukraine* 3 monthly Routine: 6 monthly Routine
Switzerland† 6 monthly (at least) At least 6 monthly (minimum, 
once virologically suppressed)
Routine
UK Every 3–4 months
Every 4–6 months 
(if stable)‡
3–6 monthly CD4 and viral load 6 monthly§
USA Adults: Every 
3–6 months¶
Children: Every 
3–4 months¶
At initiation, 2–8 weeks post 
initiation, then every 4–8 weeks 
until viral suppression achieved, 
then every 3–4 months||
Routine
*Data provided by Médecins Sans Frontières. †More frequent monitoring as considered necessary. ‡Deﬁ ned as CD4 
count >200 copies/mL and viral load <50 copies/mL for 1 year. §Already practiced in some hospitals. ¶Adults and 
children: in clinically stable patients with suppressed viral load and whose CD4 cell count has increased well above 
the threshold for opportunistic infection risk, CD4 count can be monitored every 6–12 months. ||Adults: for clinically 
and immunologically stable, adherent patients on ART for more than 2–3 years, 6 monthly monitoring of viral load 
can considered. 
Table: Current guidelines for CD4 cell count and viral load monitoring of patients receiving antiretroviral 
therapy by country
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The future of CD4 for treatment monitoring
Baseline measurements
Consistent with the trend towards earlier initiation of ART, 
the median baseline CD4 cell count at which patients start 
ART has risen in the past decade in all regions; however, 
the proportion of people initiating ART with very low CD4 
counts remains high, with more than one in four patients 
starting ART at CD4 count 100 cells per μL or less across all 
regions.32 Patients presenting with a low CD4 cell count are 
at increased risk of death in both low and high-income 
settings,33,34 and determination of CD4 count has an 
important role in decisions for screening and prophylaxis 
for major opportunistic infections. A low CD4 count is 
predictive of several diseases associated with increased 
mortality, including cryptococcal meningitis, pneumocystis 
pneumonia, toxoplasmosis, Mycobacterium avium complex, 
and disseminated cytomegalovirus disease. CD4 cell counts 
can help to stratify clinical care requirements for patients 
presenting late to care and support diagnostic decision 
making at baseline and in patients with failing ART or 
those returning to care after a period of treatment 
interruption. Cryptococcal meningitis is a leading cause 
of mortality in people with HIV/AIDS, contributing up 
to 20% of AIDS-related deaths in low-income and 
middle-income settings.35 WHO recommends systematic 
antigen screening for cryptococcal meningitis for all 
patients with CD4 counts of 100 cells per μL or lower and 
pre-emptive treatment for those who test antigen-positive.36
CD4 count also plays an important part in supporting 
decisions to start and stop co-trimoxazole prophylaxis. 
Co-trimoxazole improves survival by reducing the risk of 
death from a range of infections, including malaria, 
severe bacterial infections, Pneumocystis jiroveci 
pneumonia, and toxoplasmosis.37 To reduce morbidity 
and mortality, WHO recommends co-trimoxazole 
prophylaxis to all HIV-infected people presenting to care 
who have advanced or severe HIV disease (WHO clinical 
stage 3 or 4) or those with a CD4 count of 350 cells per μL 
or less, to be discontinued once CD4 counts rise above 
this level.38 In settings with a high prevalence of malaria 
or severe bacterial infections, WHO recommends 
starting lifelong co-trimoxazole prophylaxis irrespective 
of CD4 cell count.
Finally, a baseline CD4 measurement might have a 
role in decisions around use of nevirapine, in view of 
the potential increased risk of nevirapine-associated 
hypersensitivity reaction at increased CD4 cell counts.39
ART monitoring
Recent evidence from randomised trials and observational 
cohorts suggest that once people with HIV infection on 
ART are virologically suppressed, CD4 cell counts remain 
stable over time in most patients.
An analysis of data from the multisite ARTEMIS trial17 
showed that of 449 patients with sustained HIV-1 RNA 
suppression (<400 copies per mL) and CD4 count of 
200 cells per μL or more who were followed for 192 weeks, 
only ﬁ ve (1%) had reductions in CD4 count below 
200 cells per μL; these reductions were transient with 
follow-up results equal to or greater than 200 cells 
per μL.17 A cohort study from the USA noted that of 
832 patients followed for a median of 7·7 years, patients 
with an initial CD4 count of 300 cells per μL or more who 
were virologically suppressed (<200 copies/mL) had a 
probability of a durable CD4 count of 200 cells per μL or 
more at year 5 of 99·2% (95% CI 97·4–99·7), after 
exclusion of non-HIV causes of lymphopenia.16
Two studies from the UK support these ﬁ ndings. In 
the ﬁ rst study, 166 patients who were stable (CD4 
>500 cells per μL and virologically suppressed 
[<50 copies/mL]) were followed for a median of 
47 weeks; only ﬁ ve (3%) patients had a reduction in CD4 
count less than 350 cells per μL and these reductions 
were again transient, with all CD4 measures greater 
than 350 cells per μL at subsequent visit.40 The second 
study followed 141 stable patients with viral loads less 
than 50 copies/mL on ART and CD4 count 350 cells per 
μL or greater for a median of 2·5 years: only 13 patients 
(9%) had a drop in CD4 count during this period, of 
which eight (61%) were transient; for three patients 
(23%) the drop was explained by other treatments that 
lower the CD4 count such as interferon or chemotherapy. 
Results of CD4 monitoring did not change clinical 
management of any patients.41
Recent data from high HIV burden settings in 
sub-Saharan Africa support these ﬁ ndings. A cohort 
study from South Africa followed 5697 adult patients 
for up to 10 years on ART. Most patients with ongoing 
virological suppression maintained CD4 counts 
continuously greater than 200 cells per μL, at 2 years, 
(99·3%), at 5 years (95·8%), and at 10 years (92·9%). 
For those who were evaluable, reductions in CD4 count 
were transient in more than 90%.42 Another cohort 
study from Uganda reported that less that 43 (3%) of 
1482 who achieved a viral load of less than 400 copies 
per mL and CD4 count of 200 cells per μL had a 
subsequent reduction in CD4 cell count to less than 
Figure: Progress in viral load phase in in countries with low and middle income with time
Feasibility analysis on viral load
(assessment, costing)
Funding secured in some cases
Guidelines updated and funding secured
Piloting viral load or recently rolled
out a viral load programme
Well established viral load 
programme
Scale-up to improve access
CambodiaZambia
India
Mozambique Ethiopia
Tanzania
Swaziland
Vietnam
Indonesia
Zimbabwe
Nigeria
Uganda Rwanda
South Africa
Brazil
Thailand
Botswana
Kenya China
Malawi
Lesotho
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200 cells per μL; this reduction was transient in 
20 (83%) of 24 whose CD4 cell count was subsequently 
assessed.18
Data for children are insuﬃ  cient, but in line with adult 
studies. A cohort study from South Africa followed 
almost 6000 virologically suppressed HIV positive 
children on ART for up to 3 years and identiﬁ ed that 
sustained reductions in CD4 counts were very rare, 
especially in children older than 2 years.43 A recent 
model-based algorithm suggest that the frequency of 
CD4 cell count measures could also be reduced in 
children, with last CD4 count, last viral load, and patient 
age to predict risk of clinical disease progression.44
None of these studies reported adverse clinical events 
occurring in virologically suppressed patients with an 
unexplained reduction in CD4 count.
Criteria to stop routine CD4 cell counts for 
treatment monitoring
CD4 cell counts at baseline continue to be important for 
initial clinical management decisions, but once ART 
is initiated and patients have achieved virological 
suppression and stabilised on treatment, the additional 
value of CD4 testing in the presence of routine viral load 
monitoring is questionable. Nadir CD4 predicts the 
maximum CD4 cell count that can be expected,45,46 but 
CD4 cell counts rarely reduce with time once virological 
suppression is achieved even for patients presenting late 
for care. Most patients achieve a CD4 count greater than 
500 cells per μL after several years of ART, provided that 
the viral load remains suppressed.47–49 However, recovery 
of CD4 count is variable and a few patients might fail 
to increase despite virological suppression.50,51 These 
variabilities in CD4 recovery would not change treatment 
decisions because there is no evidence for changing ART 
in those patients with discordance between immuno-
logical and virological responses (ie, persistently low CD4 
counts despite virological suppression), although there 
would be a beneﬁ t to continue prophylaxis in such 
patients.52
A growing consensus is that monitoring of CD4 count 
adds little additional value to viral load monitoring once 
patients are stable on ART with viral suppression. 
Guidelines issued by the Southern African HIV Clinicians 
Society recommend that for patients being monitored 
with viral loads, once the CD4 count is greater than 
200 cells per μL and viral load is suppressed (ie, 
two consecutive undetectable viral loads), there is no need 
to continue CD4 testing, although CD4 testing is 
recommended if virological or clinical failure occurs. 22
For these reasons, the WHO consultation endorsed the 
move to reduce routine CD4 monitoring for adults when 
access to viral load testing is assured. For children, the 
decision to stop CD4 is more complex, both because of 
diﬀ erences in risk of disease progression, particularly for 
younger children, and determination of immunological 
recovery. A working deﬁ nition of stability on ART for 
children might need to be age-dependent, and this is an 
important area for further research (panel 1).
Community considerations
CD4 cell counts are central to approaches to treatment 
literacy, and substantial emphasis has been placed on the 
use of CD4 counts as a way to explain to patients why 
ART is needed, to reinforce the importance of 
maintaining good adherence, and to show a positive 
response to treatment. At the same time, both clinicians 
and patients recognise that CD4 cell counts can ﬂ uctuate 
substantially for biological reasons, the inherent 
variability of CD4 cell counts, and inconsistency of 
Panel 1: Implementation considerations for reducing CD4 
cell counts for antiretroviral therapy (ART) monitoring
• Retain capacity for CD4 cell counts as a diagnostic 
instrument to support ART initiation and risk 
stratiﬁ cation for provision of a late presenter package of 
care, including prophylaxis for opportunistic infections, 
and cryptococcal antigen screening
• Ensure reliable access to routine viral load monitoring as a 
prerequisite for reducing or stopping CD4 monitoring
• Ensure access to CD4 for individuals who develop clinical 
problems or evidence of virological failure while on ART
• Develop guidance to deﬁ ne a stable patient on ART in 
whom CD4 monitoring can be stopped
• Train health workers and patients in viral load literacy as a 
way to understand health status and response to treatment
• Redirect resources saved from reduced CD4 monitoring to 
support viral load monitoring
Panel 2: Research agenda for CD4 monitoring
•  CD4 dynamics in virologically suppressed patients in 
resource-limited settings
• Minimum period and criteria before CD4 cell count 
monitoring can be stopped (stable patients)
• Frequency of viral load monitoring required if CD4 
monitoring is dropped
• Validation of change in CD4 count at increased virological 
thresholds used to determine failure in resource-limited 
settings (ie, 1000 copies per mL)
• Criteria to reduce CD4 monitoring in infants and children
• Criteria to reintroduce CD4 measures (eg, viral rebound, 
or clinical event, or toxic treatment (eg, interferon for 
hepatitis C, chemotherapy)
• Management of patients with persistent discordant 
immunological virological response
• Cost and cost eﬀ ectiveness of diﬀ erent models of CD4 cell 
count versus viral load monitoring
• Deﬁ ne whether viral load criteria could replace CD4 cell 
count criteria in decisions regarding stopping primary and 
secondary opportunistic infections prophylaxis, mainly in 
resource-limited settings
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results obtained by certain CD4 tests; this can be a source 
of unnecessary anxiety for patients.53,54
If viral load is to be used as the main means to monitor 
ART, treatment literacy eﬀ orts will be needed so that it 
can take the place of CD4 counts as the main way that 
patients understand they are responding to ART. 
Successful pilot programmes have already shown that 
with appropriate communication materials the relation 
between viral load and treatment success is easy to 
convey and readily understood,55 and patients’ groups 
have expressed a willingness to support a reduction in or 
stopping of routine CD4 count monitoring for stable 
patients provided this is accompanied by clear messaging 
that patients can understand.
Directions for future research
Various research questions remain (panel 2). ART 
monitoring with or without CD4 count (as an addition to 
viral load) will unlikely be assessed in randomised trials 
because the required sample sizes to detect possible 
diﬀ erences when none are anticipated would be very 
large; attempts to do such a trial have failed for this 
reason. In the absence of evidence from randomised 
trials, the collection and reporting of observational data 
will continue to be important, in particular from 
resource-limited settings and for children on ART.
Another important area for research is to determine 
whether certain clinical decisions that are dependent on 
CD4 count, notably decisions to stop cotrimoxazole 
prophylaxis, could be made on the basis of virological 
thresholds or duration of virological suppression. Cohort 
data from Europe suggests that risk of pneumocystis 
pneumonia is low in people who are virologically 
suppressed, even at low CD4 cell counts.56
Research is also needed to identify if and when CD4 
measurement should be reinstituted (eg, viral rebound, 
clinical event, or concomitant therapy with immuno-
suppresive potential [interferon for hepatitis C or 
chemotherapy]) and to determine CD4 dynamics in 
virologically suppressed patients in resource-limited 
settings. Finally, because CD4 recovery is variable and 
might not increase despite virological suppression in some 
patients,50,51 there is a need to better understand the reason 
for discordance between immunological and virological 
measures and the value of ongoing CD4 monitoring for 
these patients,57 as well as with virological rebound.
Conclusions
CD4 cell counts have been the main instrument to make 
decisions about ART initiation and to monitor the response 
to treatment, and have had great value for both clinicians 
and patients. However, the use of ongoing CD4 monitoring 
in people who are stable on ART whose viral load is also 
being monitored and is undetectable is increasingly 
questioned, in settings with high and low income.
Almost 13 million people were on ART and more than 
2 million people were newly initiated on ART in 2013 
alone. Life-expectancy studies from both high-income58 
and low-income59–61 settings have concluded that with 
timely ART initiation, people living with HIV can expect 
to enjoy near normal life expectancy. Therefore, a 
pressing need exists to identify the most rational and 
cost eﬀ ective way to provide laboratory monitoring of 
HIV treatment over the long term.
CD4 counts will continue to play an important part in 
initial decisions around ART initiation and clinical 
management, particularly for those patients presenting 
late to care, and will remain an important instrument 
to monitor treatment in settings where viral load 
monitoring is still restricted. However, in settings 
where both CD4 and viral load testing are routinely 
available, countries should consider reducing the 
frequency of CD4 cell counts or not using them 
routinely to monitor treatment response once patients 
are stable on ART. Countries in the process of phasing 
in viral load monitoring capacity should consider 
reducing the indications for and frequency of CD4 cell 
measurements and redirecting those resources towards 
expanding access to viral load monitoring.
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